Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS
Press Releases
Ractigen Therapeutics  
November 19, 2024

Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS

NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA)

logo salamanca press

Salamanca Press

Local & Social